Elevate Your Investing Strategy:<\/p>\n
Myriad Genetics ( (MYGN)<\/a> ) just unveiled an update.<\/p>\n On October 1, 2025, Myriad Genetics<\/a> entered into a Separation Agreement with its former CFO, Scott J. Leffler, following his departure on August 15, 2025, and official separation on September 2, 2025. The agreement, effective October 9, 2025, includes a severance payment of $1,239,384 and accelerated vesting of equity awards, reflecting the company\u2019s adherence to standard executive transition practices and potentially impacting its financials and leadership dynamics.<\/p>\n The most recent analyst rating on (MYGN)<\/a> stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Myriad Genetics stock, see the MYGN Stock Forecast page<\/a>.<\/p>\n Spark\u2019s Take on MYGN Stock<\/b><\/p>\n According to Spark, TipRanks\u2019 AI<\/a> Analyst, MYGN is a Neutral.<\/p>\n Myriad Genetics\u2019 overall stock score reflects strong revenue growth and positive earnings call sentiment. However, significant challenges in profitability, cash flow management, and valuation weigh heavily on the score. The technical analysis shows short-term strength, but longer-term indicators suggest caution.<\/p>\n To see Spark\u2019s full report on MYGN stock, click here<\/a>. <\/p>\n More about Myriad Genetics<\/b><\/p>\n Myriad Genetics, Inc. operates in the biotechnology industry, focusing on genetic testing and precision medicine. The company provides diagnostic tests that help assess the risk of developing diseases, guide treatment decisions, and improve patient outcomes.<\/p>\n Average Trading Volume:<\/b> 1,732,985<\/p>\n Technical Sentiment Signal:<\/b> Sell<\/p>\n Current Market Cap:<\/b> $743.4M<\/p>\n Learn more about MYGN stock on TipRanks\u2019 Stock Analysis page<\/a>.<\/p>\n Disclaimer & Disclosure<\/a>Report an Issue<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data,…\n","protected":false},"author":3,"featured_media":284834,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[815,159,67,132,68],"class_list":{"0":"post-284833","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-science","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115335046296115854","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/284833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=284833"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/284833\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/284834"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=284833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=284833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=284833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}